Benzinga | Nov 10, 2021 05:25PM EST

Biolase Q3 Adj. EBITDA Loss $2.5M, Or $0.03/Share, Sales $9.50M Beat $8.78M Estimate

Biolase (NASDAQ:BIOL) reported quarterly sales of $9.50 million which beat the analyst consensus estimate of $8.78 million by 8.20 percent. This is a 45.28 percent increase over sales of $6.54 million the same period last year.